✦ LIBER ✦

A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas : A study of the Mayo phase 2 consortium (P2C)

✍ Scribed by Scott Okuno; Howard Bailey; Michelle R. Mahoney; Douglas Adkins; William Maples; Tom Fitch; David Ettinger; Charles Erlichman; Jann N. Sarkaria

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 175 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25928

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of a 2-arm Phase II study of 9-n

Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas

✍ Shreyaskumar R. Patel; Jennifer Beach; Nicholas Papadopoulos; M. Andrew Burgess; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 3 views

## Abstract ## BACKGROUND The authors conducted a 2‐arm Phase II trial of 9‐nitrocamptothecin (9‐NC), an oral topoisomerase I inhibitor, to define response rates in patients with gastrointestinal (GI) leiomyosarcomas and other soft‐tissue sarcomas (STS). ## METHODS Patients were required to prov

Bendamustine hydrochloride in patients w

Bendamustine hydrochloride in patients with refractory soft tissue sarcoma : A noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001)

✍ Joerg T. Hartmann; Frank Mayer; Jan Schleicher; Marius Horger; Jens Huober; Ines 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 1 views

## Abstract ## BACKGROUND. For patients with advanced soft tissue sarcoma (STS), no standard treatment is established after previous chemotherapy with anthracyclines and ifosfamide. Bendamustine hydrochloride is a bifunctional alkylating agent that is not cross‐resistant to other DNA‐interacting s

A phase II trial of paclitaxel in patien

A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A southwest oncology group study

✍ Stanley P. Balcerzak; Jacqueline Benedetti; Geoffrey R. Weiss; Ronald B. Natale 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 461 KB 👁 3 views

A two-arm phase II study of temozolomide

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas

✍ Jonathan C. Trent; Jennifer Beach; Michael A. Burgess; Nicholas Papadopolous; Le 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 2 views

## Abstract ## BACKGROUND The authors conducted a two‐arm Phase II study of temozolomide to determine its efficacy and toxicity in patients with soft tissue sarcomas (STSs) who had received, had refused, or were not eligible for standard chemotherapy with doxorubicin and ifosfamide (Arm 1) and in

A study of paclitaxel, carboplatin, and

A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma : A phase 2 Consortium study

✍ Gary A. Croghan; Vera J. Suman; William J. Maples; Mark Albertini; Gerald Linett 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

Phase 2 study of cetuximab in patients w

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

✍ Andrew X. Zhu; Keith Stuart; Lawrence S. Blaszkowsky; Alona Muzikansky; Donald P 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB 👁 1 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor (EGFR) and ligand expression is frequently seen in hepatocellular carcinoma (HCC). A phase 2 study was performed with cetuximab, a chimeric monoclonal antibody that binds specifically to EGFR, in patients with advanced HCC. ## METHODS.